Signaling antibodies in cancer therapy

This publication has 30 references indexed in Scilit:

• Monoclonal antibody therapy for B cell non-Hodgkin’s lymphomas: emerging concepts of a tumour-targeted strategy
  European Journal Of Cancer, 1999
• Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer
  Clinical Therapeutics, 1999
• Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy
  Journal of Clinical Oncology, 1999
• Human antibodies by design
  Nature Biotechnology, 1998
• POSITIVE VERSUS NEGATIVE SIGNALING BY LYMPHOCYTE ANTIGEN RECEPTORS
  Annual Review of Immunology, 1998
• The association between CD20 and Src-family Tyrosine kinases requires an additional factor
  Molecular Immunology, 1998
• The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase
  Oncogene, 1998
• Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs
  Cancer Biotherapy & Radiopharmaceuticals, 1997
• Prevention of breast tumour development in vivo by downregulation of the p185neureceptor
  Nature Medicine, 1995
• IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.
  Proceedings of the National Academy of Sciences, 1982